The efficacy of dexketoprofen for migraine attack

Yang, Baofeng; Xu, Zuojun; Chen, Linglong; Chen, Xinguo; Xie, Yuequn

doi:10.1097/md.0000000000017734

Cited by 7 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The guidelines of the European Federation of Neurological Societies recommend triptans, acetylsalicylic acid, naproxen, ibuprofen, diclofenac, and paracetamol as the first-line medication options. 29 Yang et al 7 reviewed and performed a meta-analysis of five studies published between 2014 and 2016, in which dexketoprofen 50 mg compared with placebo or frovatriptan 2.5 mg combined with dexketoprofen 37.5 mg compared with frovatriptan 2.5 mg plus placebo. They reported that dexketoprofen was a good treatment option in pain relief in patients with migraine, with a reduced need for rescue drugs, and with no significant increase in side effects.…”

Section: Discussionmentioning

confidence: 99%

“…They reported that dexketoprofen was a good treatment option in pain relief in patients with migraine, with a reduced need for rescue drugs, and with no significant increase in side effects. 7 Many studies have investigated the efficacy of mesotherapy on pain relief in health conditions other than migraine. 12 , 14 , 30 , 31 Those studies reported that mesotherapy can be a good treatment option for pain relief when compared to different analgesics.…”

Section: Discussionmentioning

confidence: 99%

“… 6 Systemic therapy of dexketoprofen can provide pain control at 45 minutes to 48 hours and reduce rescue drug need with no significant increase in adverse events in patients with a migraine attack. 7 , 8 A double-blind randomized controlled study of 279 migraine patients found that the combination of frovatriptan and dexketoprofen was more efficient than frovatriptan alone for the treatment of migraine attacks. 9 Also there are so many nonpharmaceutical methods in migraine treatment which include non-invasive neuromodulation, nutraceuticals such as riboflavin and magnesium, and behavioral treatment approaches.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intradermal mesotherapy versus intravenous dexketoprofen for the treatment of migraine headache without aura: a randomized controlled trial

Akbaş

Koçak²,

Koçak

et al. 2021

Ann Saudi Med

View full text Add to dashboard Cite

BACKGROUND: Migraine is a prevalent disabling primary headache disorder that is classified into two major types: migraine without aura and migraine with aura. New therapeutic methods to reduce migraine headaches in the emergency department (ED) include intradermal mesotherapy. OBJECTIVE: Compare the efficacy of intradermal mesotherapy versus a systemic therapy in pain control in patients with headache related to migraine without aura. DESIGN: Prospective parallel-group randomized controlled trial. SETTING: University hospital in Turkey. PATIENTS AND METHODS: Patients 18 years of age and older who were admitted to the ED over a 15-month period with headache related to migraine without aura were eligible for inclusion if they had a VAS score of 4 or above. Patients were randomly allocated to one session of mesotherapy or intravenous dexketoprofen. Changes in pain intensity were measured by the score on a visual analog scale (VAS) at 30, 60, and 120 minutes and 24 hours after treatment. Efficacy was also assessed by the need for use of an analgesic drug within 24 hours, by readmission with the same complaint to the ED within 72 hours, and by adverse effect rates. MAIN OUTCOME MEASURE: Pain intensity on the VAS scale. SAMPLE SIZE: 148 patients (154 enrolled and treated; 1 patient in the mesotherapy and 5 patients in the systemic therapy group lost to follow up). RESULTS: Pain intensity on the VAS scale decreased from a median score of 8 to 4 in the mesotherapy group and from 8 to 5 in the systemic therapy group. These differences were statistically significant from baseline for all time intervals ( P =.001 to 30 minutes, P =.004 to 60 minutes, P =.005 to 120 minutes, and P =.002 to 24 hours). The need to use analgesics and the rate of readmission to the ED were higher in the systemic therapy group ( P =.013 and P =.030, respectively). Adverse effect rates were minimal and similar in the study groups during the one-week follow-up period. CONCLUSIONS: Mesotherapy is more efficacious than intravenous dexketoprofen in the management of acute attack of migraine without aura in the ED. LIMITATIONS: Unblinded. Valid for assessing short-term pain relief, but not sufficient to predict long-term efficacy. Not generalizable because single center and small sample size. CONFLICT OF INTEREST: None. REGISTRATION: ClinicalTrials.gov (NCT04519346)

show abstract

Section: Discussionmentioning

confidence: 99%